Diflomotecan
Diflomotecan (BN 80915) is a potent and orally active inhibitor of topoisomerase I. Diflomotecan (BN 80915) causes enhanced plasma stability and has the superior preclinical anti-tumour activity compared with other established compounds[1][2].
Product Specifications
CAS Number
220997-97-7
Product Name Alternative
BN 80915
UNSPSC
12352005
Target
Topoisomerase
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/diflomotecan.html
Solubility
10 mM in DMSO
Smiles
O=C(OC1)C[C@](O)(CC)C2=C1C(N3CC4=CC5=CC(F)=C(F)C=C5N=C4C3=C2)=O
Molecular Formula
C21H16F2N2O4
Molecular Weight
398.36
References & Citations
[1]Kroep JR, et al. Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009;18 (1) :69-75.|[2]Gelderblom H, et al. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res. 2003;9 (11) :4101-4107.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![2- (4-Nitro-phenyl) -imidazo[1,2-a] pyrimidine](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
NBP2-97450AF700 0.1 mL
Rabbit Polyclonal RanBP3 Antibody [Alexa Fluor 700]
Sign In for Pricing
View Details 057806-01 10 µg
Eukaryotic Cluster Of Differentiation 5 (CD5), Recombinant, Human, His-Tag
Sign In for Pricing
View Details